{
}
Roche Holdings has finalized its tender offer to acquire Poseida Therapeutics for approximately $1.5 billion, agreeing to pay $9.00 per share for nearly 65 million shares, representing 66% of Poseida’s outstanding stock. The deal includes a potential additional payment of up to $4.00 per share. Following the acquisition, Poseida will become a wholly owned subsidiary of Roche, and its shares will be delisted from the Nasdaq Global Select Market.
Roche is set to finalize its acquisition of Poseida Therapeutics, securing a 66.1% stake after a successful tender offer that saw over 64.9 million shares tendered. The deal, valued at nine dollars per share with potential additional payments, will make Poseida a wholly-owned subsidiary, leading to its delisting from Nasdaq.
Roche is set to finalize its $1.5 billion acquisition of U.S. biopharma company Poseida Therapeutics, specializing in complex immune cell therapies for blood cancer. The deal involves Roche accepting nearly 65 million shares, representing 66% of Poseida's stock, at $9 per share, with potential additional payments. Poseida will become a wholly owned subsidiary, enhancing Roche's portfolio with allogeneic CAR-T cell therapies for cancer and autoimmune diseases.
Roche's subsidiary, Blue Giant Acquisition Corp., has successfully completed a tender offer for Poseida Therapeutics, acquiring approximately 66.11% of its shares at $9.00 each, plus a contingent value right of up to $4.00 per share. Following the tender offer's expiration, Roche will merge with Poseida, making it a wholly owned subsidiary, with its shares ceasing to trade on Nasdaq. Poseida is known for its innovative allogeneic cell therapies and genetic medicines aimed at addressing significant medical needs.
Poseida Therapeutics has announced that the US waiting period for its $1.5 billion acquisition by Roche has expired, as confirmed in a filing with the US Securities and Exchange Commission. This marks a significant step forward in the deal's progression.
Roche has received approval from US antitrust authorities for its $1.5 billion acquisition of Poseida Therapeutics. This clearance marks a significant step in Roche's expansion within the biotech sector, enhancing its portfolio and capabilities in innovative therapies.
Roche's decision to acquire Poseida Therapeutics for $1 billion upfront came after initial reluctance, as filings reveal that partner Astellas did not submit an offer. Prior to Roche's announcement, another undisclosed pharmaceutical company had expressed interest in Poseida's cell therapy assets.
Roche has initiated a tender offer for all outstanding common shares of Poseida Therapeutics at nine dollars per share in cash, along with a contingent value right (CVR) for potential additional payments of up to four dollars per share. The offer will expire on January 7, pending regulatory approvals and the valid tender of a majority of shares.
Roche has initiated a tender offer for all outstanding shares of Poseida Therapeutics at $9.00 per share in cash, along with a contingent value right for potential additional payments of up to $4.00 per share. This offer follows a merger agreement dated November 25, 2024, and will expire on January 7, 2025, unless extended. Roche has filed the necessary documentation with the United States Securities and Exchange Commission.
Poseida Therapeutics, Inc.
Companies
| Symbol | PSTX |
| Name | Poseida Therapeutics, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | San Diego |
| Zipcode | 92121 |
| Website | http://www.poseida.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
roche completes 1.5 billion acquisition of poseida therapeutics
11:14 08.01.2025
roche set to finalize acquisition of poseida therapeutics today
10:55 08.01.2025
Roche finalizes 1.5 billion dollar acquisition of Poseida Therapeutics
07:44 08.01.2025
roche completes acquisition of poseida therapeutics in tender offer transaction
07:10 08.01.2025
Poseida Therapeutics acquisition by Roche receives US regulatory approval
14:29 07.01.2025
Roche secures US approval for Poseida Therapeutics acquisition worth 1.5 billion
14:23 07.01.2025
roche's unexpected acquisition of poseida therapeutics for one billion dollars
15:24 10.12.2024
roche initiates takeover bid for poseida therapeutics at nine dollars per share
07:48 10.12.2024
Roche launches tender offer for Poseida shares at nine dollars each
22:35 09.12.2024
roche initiates tender offer for poseida therapeutics at nine dollars per share
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Industry Mergers & Acquisitions
Stock Market Updates
Government Economic Policies
Energy Sector Developments
AI Applications
Private Equity Deals
Funding Rounds & Investments
Fintech Startups
CEO Changes
AI Innovations
Emerging Startups
Global Financial Events
Central Bank Actions
Venture Capital Investments
Countries:
Companies:
Apple Inc.
Google Inc.
Tesla, Inc.
Amazon.com, Inc.
Tesmec S.p.A.
OpenAI ERC USD
Microsoft Corporation
Walmart Inc.
Alphabet Inc.
SWIGGY LIMITED
Foxconn Technology Co., Ltd.
Hollywood Bowl Group PLC
NASDAQ Composite
Wise plc
Mastercard Inc
Mistral 1
TENCENT
NVIDIA Corporation
Nippon Steel Corp
Netflix, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
British Pound Sterling
Japanese Yen
United Arab Emirates Dirham
Vietnamese Đồng
New Zealand Dollar
Saudi Riyal
Thai Baht
Australian Dollar
Indonesian Rupiah
Singapore Dollar
Omani Rial
Bahraini Dinar
Qatari Riyal
Algerian Dinar
Egyptian Pound
South Korean Won
People: